| Literature DB >> 33185875 |
Sonia Schuepbach-Mallepell1, Christine Kowalczyk-Quintas1, Angela Dick2, Mahya Eslami1, Michele Vigolo1, Denis J Headon3, Michael Cheeseman3, Holm Schneider2, Pascal Schneider4.
Abstract
Genetic deficiency of ectodysplasin A (EDA) causes X-linked hypohidrotic ectodermal dysplasia, a congenital condition characterized by the absence or abnormal formation of sweat glands, teeth, and several skin appendages. Stimulation of the EDA receptor (EDAR) with agonists in the form of recombinant EDA or anti-EDAR antibodies can compensate for the absence of Eda in a mouse model of Eda deficiency, provided that agonists are administered in a timely manner during fetal development. Here we provide detailed protocols for the administration of EDAR agonists or antagonists, or other proteins, by the intravenous, intraperitoneal, and intra-amniotic routes as well as protocols to collect blood, to visualize sweat gland function, and to prepare skulls in mice.Entities:
Keywords: Amniotic fluid; EDAR signaling; Ectodermal dysplasia; Protein replacement therapy; Route of administration
Mesh:
Substances:
Year: 2021 PMID: 33185875 DOI: 10.1007/978-1-0716-1130-2_12
Source DB: PubMed Journal: Methods Mol Biol ISSN: 1064-3745